Comparative Pharmacology
Head-to-head clinical analysis: ERYC 125 versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC 125 versus ZMAX.
ERYC 125 vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also activates motilin receptors in the gastrointestinal tract, enhancing gastric motility.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
1.5-2.0 hours in adults; prolonged in hepatic impairment (up to 5-6 hours) or neonates.
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Primarily hepatic metabolism; ~2-5% excreted unchanged in urine, ~15-20% in bile/feces as active drug.
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic